These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22113766)

  • 1. Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Pant S; Neupane P; Ramesh KC; Barakoti M
    Cardiol J; 2011; 18(6):712-7. PubMed ID: 22113766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    Tamhane U; Meier P; Chetcuti S; Chen KY; Rha SW; Grossman MP; Gurm H
    EuroIntervention; 2009 Aug; 5(3):384-93. PubMed ID: 19736165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
    Behr T; Kuch B; Behr W; von Scheidt W
    Clin Res Cardiol; 2011 Oct; 100(10):907-14. PubMed ID: 21533581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.
    Lee SP; Suh JW; Park KW; Lee HY; Kang HJ; Koo BK; Chae IH; Choi DJ; Rha SW; Bae JW; Cho MC; Kwon TG; Bae JH; Kim HS;
    Trials; 2010 Aug; 11():87. PubMed ID: 20735821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cilostazol in percutaneous coronary interventions.
    Rogers KC; Faircloth JM; Finks SW
    Ann Pharmacother; 2012 Jun; 46(6):839-50. PubMed ID: 22669796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Norgard NB; Abu-Fadel M
    Vasc Health Risk Manag; 2009; 5():873-82. PubMed ID: 19898643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
    Motovska Z; Widimsky P
    Vasc Health Risk Manag; 2009; 5(1):475-81. PubMed ID: 19475783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
    J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
    Rossi M; Serraino GF; Spadafora A; Renzulli A
    Interact Cardiovasc Thorac Surg; 2012 Jul; 15(1):115-21. PubMed ID: 22457187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.
    Singh I; Shafiq N; Pandhi P; Reddy S; Pattanaik S; Sharma Y; Malhotra S
    Br J Clin Pharmacol; 2009 Jul; 68(1):4-13. PubMed ID: 19659998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Platelet function: new drugs, new assays : possible impacts on operative medicine?].
    Mahla E; Höchtl T; Prüller F; Freynhofer MK; Huber K
    Anaesthesist; 2012 Jun; 61(6):483-96. PubMed ID: 22695779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
    Jeong YH; Park Y; Kim IS; Yun SE; Kang MK; Hwang SJ; Kwak CH; Hwang JY
    Thromb Haemost; 2010 Dec; 104(6):1286-9. PubMed ID: 20838742
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
    Lotfi A; Cui J; Wartak S; Columbo J; Mulvey S; Davis M; Schweiger M; Giugliano GR
    Clin Cardiol; 2011 Sep; 34(9):567-71. PubMed ID: 21792981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of prasugrel in a patient with clopidogrel hypersensitivity.
    Peppard SR; Held-Godgluck BM; Beddingfield R
    Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Faxon DP; Lawler E; Young M; Gaziano M; Kinlay S
    Circ Cardiovasc Interv; 2012 Jun; 5(3):372-80. PubMed ID: 22668555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
    Lee BK; Lee SW; Park SW; Lee SW; Park DW; Kim YH; Lee CW; Hong MK; Kim JJ; Jang S; Chi HS; Park SJ
    Am J Cardiol; 2007 Aug; 100(4):610-4. PubMed ID: 17697815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.